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Background: Hypocretins/orexins (Hcrt/Ox) are hypothalamic neuropeptides involved in sleep-wakefulness regulation.
Deficiency in Hcrt/Ox neurotransmission results in the sleep disorder narcolepsy, which is characterized by an inability
to maintain wakefulness. The Hcrt/Ox neurons are maximally active during wakefulness and project widely to the
ventral tegmental area (VTA). A dopamine-containing nucleus projecting extensively to the cerebral cortex, the VTA
enhances wakefulness. In the present study, we used retrograde tracing from the medial prefrontal cortex (mPFC)
to examine whether Hcrt1/OxA neurons target VTA neurons that could sustain behavioral wakefulness through their
projections to mPFC.
Results: The retrograde tracer Fluorogold (FG) was injected into mPFC and, after an optimal survival period, sections
through the VTA were processed for dual immunolabeling of anti-FG and either anti-Hcrt1/OxA or anti-TH antisera.
Most VTA neurons projecting to the mPFC were located in the parabrachial nucleus of the ipsilateral VTA and were
non-dopaminergic. Only axonal profiles showed Hcrt1/OxA-immunoreactivity in VTA. Hcrt1/OxA reactivity was observed
in axonal boutons and many unmyelinated axons. The Hcrt1/OxA immunoreactivity was found filling axons but it
was also observed in parts of the cytoplasm and dense-core vesicles. Hcrt1/OxA-labeled boutons frequently apposed
FG-immunolabeled dendrites. However, Hcrt1/OxA-labeled boutons rarely established synapses, which, when they were
established, were mainly asymmetric (excitatory-type), with either FG-labeled or unlabeled dendrites.
Conclusions: Our results provide ultrastructural evidence that Hcrt1/OxA neurons may exert a direct synaptic influence
on mesocortical neurons that would facilitate arousal and wakefulness. The paucity of synapses, however, suggest that
the activity of VTA neurons with cortical projections might also be modulated by Hcrt1/OxA non-synaptic actions. In
addition, Hcrt1/OxA could modulate the postsynaptic excitatory responses of VTA neurons with cortical projections to
a co-released excitatory transmitter from Hcrt1/OxA axons. Our observation of Hcrt1/OxA targeting of mesocortical
neurons supports Hcrt1/OxA wakefulness enhancement in the VTA and could help explain the characteristic hypersomnia
present in narcoleptic patients.
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The ventral tegmental area (VTA) comprises several
subdivisions including the paranigral (PN), parabrachial
(PBP) or interfascicular (IF) nuclei [1]. Neurons synthesizing
neurotransmitters, such as dopamine (DA), GABA or
glutamate among others coexist in these VTA divisions
[2,3]. The mesocortical system, which is strongly involved
in cognitive behavior, EEG activation and arousal, is
formed by VTA projections to areas of the cerebral cortex
located mainly in the medial surface of the frontal lobe
[4]. VTA neurons projecting to the medial prefrontal
cortex (mPFC) are distributed throughout both the PBP
and PN [5]. Although much emphasis has been placed on
the dopaminergic mesocortical system in previous studies,
some reports indicate that GABA-containing VTA neurons
also project to the mPFC [6]. Moreover, GABAergic VTA
neurons are active during wakefulness [7]. VTA stimulation
produces inhibition of cortical pyramidal neurons through
activation of both GABA cortical interneurons and GABA
mesocortical VTA neurons [8,9]. However, systematic
studies assessing the relative contributions of dopaminergic
and non-dopaminergic neurons to the mesocortical
pathway reaching mPFC have not been addressed so far.
Hypothalamic neurons containing the peptides
Hypocretins/orexins (Hcrt/Ox) project widely to the
VTA [10-12]. The Hcrt/Ox peptide family involved in
sleep-wakefulness regulation comprises two peptides:
Hcrt1/OxA and Hcrt2/OxB. Hcrt1/OxA binds to Hcrt/
Ox-R1 and Hcrt/Ox-R2, both of which are present in VTA
neurons [13]. Deficient actions of Hcrt/Ox due to either
degeneration of Hcrt/Ox neurons or breakdown of Hcrt/
Ox signaling pathways result in the chronic sleep disorder
narcolepsy, which is characterized by inability to maintain
prolonged periods of wakefulness [14-16]. Furthermore,
Hcrt/Ox neurons discharge maximally in wakefulness,
decrease their activity in slow wave sleep and cease firing
during REM sleep [17,18].
Intracerebroventricular Hcrt/Ox increase mPFC DA
release and neuronal activity, and thereby arousal [19,20].
Moreover, Hcrt1/OxA infusion in the VTA increases wake-
fulness and decreases sleep [21]. Hcrt1/OxA application
in vitro enhances VTA neuron activity [22], suggesting that
Hcrt1/OxA excites the mPFC partly though activation of
mesocortical VTA neurons.
A 2007 study has reported the existence of only a few
synapses between Hcrt1/OxA axons and VTA neurons;
some of these neurons were identified as either
dopaminergic or GABAergic [23]. Thus, Hcrt1/OxA could
affect VTA function synaptically, but also perhaps through
non-synaptic actions that have been reported typical of
peptidergic transmission [24,25]. Here we hypothesize that
some of those neurons targeted by Hcrt1/OxA axons
belong to the mesocortical pathway. Nevertheless,
there are no ultrastructural studies about particularrelationships between Hcrt1/OxA axons and VTA
neurons projecting unambiguously to mPFC, and the
definite targeting of mesocortical neurons by Hcrt1/OxA
axons has not been assessed yet.
Here we determine: 1) the comparative contribution of
VTA dopaminergic and non-dopaminergic neurons to
mesocortical projections to mPFC; 2) the ultrastructural
distribution of Hcrt1/OxA in the VTA; and 3) the cellular
relationships of Hcrt1/OxA-containing axons with VTA
neurons projecting to mPFC. The results obtained identify
ultrastructural bases for hypocretinergic activation of
VTA mesocortical neurons and improveour understanding
of the anatomical linkages supporting the well-known
wake-enhancing and cortical activation actions of Hcrt1/
OxA at the VTA.
Results
Injection sites
The animals were classified in three groups according to
the mPFC injection sites. The first group comprised ten
animals with Fluorogold (FG) injections located exclusively
in the prelimbic sector (PL) of mPFC (Figure 1A,B). In
another eight animals, the FG deposit also included either
the medial orbital sector (MO; n = 4) or the cingular sector
(Cg1; n = 4) of mPFC. In sixteen animals, the retrograde
tracer stained all layers of the cerebral cortex; in one
animal (R31; PL) the FG deposit was mainly in super-
ficial layers (layers I - IV; PL) and in another animal
(R40; Cg1-PL) the FG injection was confined to layers
I-V (Cg1-PL).
Single immunochemical detection of Fluorogold
All the animals had FG-immunolabeled neurons in
VTA, but these neurons were also observed in some
other brainstem regions such as the locus coeruleus,
dorsal raphe nucleus and laterodorsal tegmental nucleus.
A few FG-immunoreactive neurons were also found in
the pedunculopontine nucleus, lateral parabrachial
nucleus, caudal linear nucleus and median and pontine
raphe nuclei (Figure 1C-F).
FG-immunoreactivity was observed in cell bodies and
dendrites of VTA multipolar neurons (Figure 1G,H).
The FG-immunolabeled neurons were largely localized
in the VTA ipsilateral to the injection site (n = 18;
87.14% ± 1.57%; Figure 1E,F,G; 2A). The ipsilateral versus
contralateral distribution of FG retrogradely-labeled
neurons was quite alike in the three injection groups
(Table 1), and FG-labeled neurons were significantly
more frequent in ipsilateral than contralateral VTA in the
three injection site groups (PL: F1,18 = 524.29; p < 0.0001;
Cg1-PL F1,6 = 2363.40; p < 0.0001; PL-MO F1,6 = 556.97;
p < 0.0001; Table 1). In most of the animals (n = 15),
FG-immunolabeled neurons were evident throughout the
entire rostro-caudal extension of the VTA, although in the
Figure 1 Location of Fluorogold (FG) injections in the prelimbic region (PL) of the medial prefrontal cortex and FG-labeled neurons in the
ventral tegmental area (VTA). (A) Sagittal scheme shows all FG infusions in PL (n = 10; modified from Swanson, 1998). (B) Coronal section showing
an FG deposit in PL using immunohistochemistry in one animal. (C-D) Representative coronal brainstem drawings showing FG-immunolabeled
neurons (red dots) in the VTA of one of the PL group rats. (E) Nissl-stained section adjacent to the section shown in F, which delineates the subdivisions
of VTA. (F) Panoramic photomicrograph showing FG-labeled neurons in the parabrachial subdivision (PBP) of VTA. (G) High magnification of box “G” from
F showing FG-labeled neurons in the PBP of VTA ipsilateral to the FG injection site. The peroxidase immunoreaction product can be clearly observed in
the cytoplasm of cell bodies and proximal dendritic branches (arrow). (H) High magnification of box “H” from F, showing much weaker FG-retrograde
labeling (arrow) in the PBP of VTA contralateral to the FG injection. ac, anterior commissure; Cg1, cingular cortex, CLi, caudal linear raphe nucleus;
DRN, dorsal raphe nucleus; Fm, forceps minor of the corpus callosum; fr, fasciculus retroflexus; IF, interfascicular subdivision of VTA; IP,
interpeduncular nucleus; M2, secondary frontal cortex; mlf, medial longitudinal fasciculus; MO, medial orbital cortex; ob, olfactory bulb; mp,
mammillary peduncle; PAG, periaqueductal gray; PN, paranigral subdivision of VTA; ri, rhinal incisure; RLi, rostral linear raphe nucleus; RN,
red nucleus; rs, rhinal sulcus; SC, superior colliculus; SNc, substantia nigra pars compacta; SNr, substantia nigra pars reticulata;. Scale bars,
B, 1 mm, E-F, 500 μm, G-H, 100 μm.
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Table 1 Fluorogold-labeled neurons in the ventral
tegmental area by either immunofluorescence or
immunohistochemistry
PL (%) PL-MO (%) Cg1-PL (%)
IH Ipsilateral 84.18 ± 2.11 93.63 ± 2.61 88.06 ± 1,11
contralateral 15.82 ± 2.11 6.37 ± 2.61 11.94 ± 1.11
IF Ipsilateral 85.60 ± 4.77 90.47 ± 3.17 85.56 ± 6.93
contralateral 14.40 ± 4.77 9.53 ± 3.17 14.44 ± 6.93
Percentage of Fluorogold (FG)-immunoreactive neurons (Mean ± SE) within the
ipsilateral and the contralateral ventral tegmental area to the FG injection site
in the three injection site groups using immunohistochemistry (IH) or
immunofluorescence (IF) techniques. Cg1: cingular cortex (n = 4 animals); MO:
medial orbital cortex (n = 4 animals); PL: prelimbic cortex (n = 10 animals).
Percentages were calculated from the FG-immunolabeled neurons counted in
8 vibratome sections per animal in IH experiments and in 5 vibratome sections
per animal in IF experiments.
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they were only observed in rostral VTA. Moreover,
retrograde-labeled neurons were more frequent in
the parabrachial subdivision (PBP; 61.96% ± 2.11%;
Figure 1E-H) than in the paranigral subdivision (PN)
of the VTA (26.66% ± 2.32%). Lower proportions of
FG-labeled neurons were observed in the interfascicular
subdivision (IF) of the VTA (6.79% ± 1.43%) and in
rostral and caudal linear raphe nuclei (4.59% ± 1.29%).
FG-immunoreactive neurons were more densely
grouped in medial and ventral portions of VTA. This
distribution pattern for FG neurons in the different
VTA subnuclei was independent of the injection site
(F6,60 = 63.53; p = 1.02).Figure 2 Bar graphs summarizing the percentage distribution of Fluo
immunolabeling techniques in the ipsilateral and the contralateral ve
or PL-MO sectors of the medial prefrontal cortex. (A) Bar graph showin
with either DAB-immunohistochemistry (IH) or immunofluorescence (IF) m
FG injection site in the medial prefrontal cortex. Percentages (mean ± SE) w
from 144 vibratome sections in 18 rats. ANOVA (animal X immunolabeling met
hoc Fisher test, factor: labeling side]. (B) Bar graph showing the proportions of
neurons observed in either ipsilateral (ipsi) or contralateral (contra) VTA
side X single or dual labeling) was used for statistical comparisons [*p <
graph showing the percentage of single FG- and double FG/TH-immuno
cingulate cortex; MO, medial orbital cortex; PL, prelimbic cortex. ANOVA (anim
comparisons [*p < 0.0001; post hoc Fisher test, factor: single or dual labe
the numbers (466 FG-labeled neurons) obtained from 90 vibratome sectDual immunofluorescent detection of Fluorogold and
Tyrosine Hydroxylase
The distribution and morphology of the FG-immuno-
fluorescent neurons in mPFC-injected animals were very
similar to those described above observed using the immu-
noperoxidase technique (n = 18; ipsilateral 86.69% ± 3.04%;
contralateral 13.31% ± 3.04%; Figure 2A), and did not differ
significantly with injection site (PL, PL-MO, Cg1-PL;
F2,30 = 0.416; p = 0.66, Table 1). The location of FG-labeled
neurons in the different subdivisions of VTA was similar to
the location observed using immunohistochemical staining
(χ23 = 2.57; p = 0.46).
In the VTA, less than 30% of the FG-immunoreactive
neurons also contained TH (n = 18; 26.05% ± 5.65%;
Figures 2B, and 3); this proportion was similar in
both the ipsilateral and contralateral VTA (Figure 2B).
ANOVA showed that FG/TH-immunolabeled neurons
were statistically less numerous than single FG-labeled
neurons (F1,34 = 35.91; p < 0.0001) and this was observed
in animals after injections in PL (F1,18 = 72.27; p < 0.0001)
and PL-MO group (F1,6 = 16.90; p = 0.006) but not in the
Cg1-PL group (F1,6 = 0.29; p = 0.61; Figure 2C). Three ani-
mals (PL, R24, R36; Cg1-PL, R30) did not have FG-labeled
neurons in the VTA contralateral to the injection site.
Single immunochemical detection of Hcrt1/OxA
Midbrain sections from four rats without an FG injection
in mPFC were immunolabeled for Hcrt1/OxA. Hcrt1/
OxA-immunoreactive axons were observed throughout
the whole rostro-caudal and dorso-ventral extents ofrogold (FG) neurons obtained with the different types of
ntral tegmental area to the FG injection site in either PL, Cg1-PL
g the percentage distribution of FG-immunolabeled neurons detected
ethods in the ventral tegmental area ipsilateral and contralateral to the
ere calculated based on the numbers (961 FG-labeled neurons) obtained
hod X labeling side) was used for statistical comparisons [*p < 0.0001; post
single FG- and double FG/tyrosine hydroxylase (TH)-immunolabeled
in tissue double processed for FG and TH. ANOVA (animal X labeling
0.0001; post hoc Fisher test, factor: single or dual labeling]. (C) Bar
labeled neurons observed in the three injection groups. Cg1, anterior
al X injection site X single or dual labeling) was used for statistical
ling]. In B and C percentages (mean ± SE) were calculated based on
ions in 18 rats.
Figure 3 Confocal photomicrographs showing Fluorogold (FG)- and/or tyrosine hydroxylase (TH)-labeled neurons in the ventral
tegmental area (VTA) of an animal with an FG injection in the prelimbic cortex. (A-C), Biomappings showing green FG-labeling (A), red
TH-labeling (B) and both (FG/TH) labelings (orange) in the merged image (C). (D-F), High power confocal photomicrographs of the boxed area
in A corresponding to the VTA ipsilateral to the FG injection, depicting FG (D), TH (E) and their merged images (F). Arrowhead marks one VTA neuron
dually labeled for FG and TH. Scale bar, A-C, 400 μm; D-F, 40 μm.
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Hcrt1/OxA containing axons were scattered enough to
make it possible to distinguish their varicosities and axon
trail quite easily (Figure 4A,B). The diameter of Hcrt1/
OxA-immunoreactive varicosities was 0.351 ± 0.103 μm,
(mean ± standard error) as measured with ImageJ software
at 100× magnification (n = 582), whereas intervaricose
Hcrt1/OxA-immunoreactive segments were always less
than 0.236 μm wide.
Dual immunohistochemical detection of Fluorogold and
Hcrt1/OxA
Observation of the tissue sections dually labeled for FG and
Hcrt1/OxA only showed that a very few FG retrograde-
labeled neurons and Hcrt1/OxA containing varicositieswere apposed to each other in the same focal plane at light
microscope level (Figure 4C,D), suggesting that cellular
contacts might be unusual between FG-immunoreactive
neurons and Hcrt1/OxA-labeled axons in the VTA.
Six animals with PL injections were analyzed for dual
FG- and Hcrt1/OxA-labeling with the electron microscope.
FG peroxidase immunoreaction product was observed in
the cytoplasm, multivesicular bodies and lysosomes of cell
bodies and dendrites. Hcrt1/OxA was only found in axonal
profiles. Hcrt1/OxA-immunoprecipitate was observed in
the cytoplasm, in dense-cored vesicles (dcv) and in large
dense-cored vesicles (ldcv), usually filling the profiles
completely (Figure 5A-C). However, in some axons
Hcrt1/OxA was exclusively observed in vesicles and/or
discrete portions of the cytoplasm (Figure 5B,D-F).
Figure 4 Hcrt1/OxA immunoreactivity in the ventral tegmental area (VTA). (A) Coronal section showing Hcrt1/OxA-immunoreactive
fibers in the VTA. (B) High magnification of boxed area in A illustrating Hcrt1/OxA-containing axons. Arrowheads point to Hcrt1/OxA varicose
axons in the parabrachial subdivision of VTA. (C) Double immunolabeling for Fluorogold (DAB, brown immunoprecipitate) and Hcrt1/OxA
(DAB-nickel, black immunoprecipitate) in the VTA. (D) High magnification of boxed area in C, showing an Hcrt1/OxA containing axon
(arrowhead) close to a Fluorogold-labeled neuron (arrow) within the parabrachial subdivision of VTA ipsilateral to the injection site. IP, interpeduncular
nucleus; PAG, periaqueductal gray; PN, paranigral subdivision of the VTA; CLi, caudal linear raphe nucleus; cp, cerebral peduncle; RN, red nucleus. Scale
bar, A,C, 500 μm; B,D, 100 μm.
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the whole thickness of the VTA sections, indicating
optimum antiserum penetration. There were no significant
variations in Hcrt1/OxA-immunoreactive axon area density
(number of labeled profiles per square micrometer of
analyzed surface) between animals (F5,50 = 2.36; p = 0.06)
or ultrathin sections (F13,42 = 0.93; p = 0.53). These
findings demonstrate that Hcrt1/OxA-immunoreactivity
in our sample was quite homogeneous. Most axonal
profiles that contained Hcrt1/OxA were unmyelinated
axons (diameter ≤ 0.235 μm; n = 1558; 67.42% ± 4.75%;
Figure 5B,C) and some profiles were varicosities (diameter
0.236-0.699 μm; n = 579; 29.76% ± 4.26%; Figure 5A,F).
There were also a few axon terminals (diameter ≥ 0.700 μm;
n = 37; 1.71% ± 0.50%; Figure 5D,E). Three animals (R35,
R36, R38) showed a few Hcrt1/OxA myelinated axons
(n = 12; 1.11% ± 0.75%). The distribution of the different
axonal profile types (myelinated, unmyelinated, varicosity
and terminal) in a sample that contained all the profile
types of Hcrt1/OxA axons and in another sample contain-
ing only axons with a circularity ≥ 0.7 was not significantly
different (χ23 = 0.64; p = 0.89). This shows that the criterion
used for measuring axon diameter was a good estimate oftheir real diameter, thus validating the utilization of the
whole axonal sample.
Unmyelinated Hcrt1/OxA-immunolabeled axons were
mainly sectioned on a transverse plane (76.84% ± 1.83%;
Figure 5B), but they were also sometimes observed in
non-transverse or longitudinal cross-sectioned planes
(Figure 5C). The ANOVA test showed that there were
no significant variations between animals regarding
the preferential transverse sectioning of Hcrt1/OxA axons
(F5,16 = 0.40; p = 0.84) (data not shown). Longitudinally-
sectioned unmyelinated Hcrt1/OxA-labeled axons fre-
quently showed dcv and ldcv. Most Hcrt1/OxA-labeled
axons were grouped with other axons in bundles within
the neuropil and did not make contacts with VTA
profiles, suggesting that they would mainly be en passant
fibers traversing the VTA towards other brain regions.
Hcrt1/OxA-immunolabeled axonal boutons were also
mostly cut transversely (94.85% ± 1.07%) in our ultrathin
sections, and there were no statistical differences between
animals in the preferential transverse sectioning of
Hcrt1/OxA containing boutons (F5,16 = 1.22; p = 0.34)
(data not shown). The varicosities were the main
Hcrt1/OxA-immunoreactive axonal bouton type (94.58%
Figure 5 Subcellular location of Hcrt1/OxA-immunoreactivity in axonal profiles of the ventral tegmental area. (A) Hcrt1/OxA location in an
axon sectioned so that the same image contains a preterminal varicose enlargement (Hcrt1/OxA-V; 1; diameter = 0.347 μm) connected to a short
narrowing of the axon (2; diameter = 0.125 μm). (B) Hcrt1/OxA-immunolabeled transverse-sectioned unmyelinated axons (Hcrt1/OxA-Ax). Note that one
of the axons only shows the Hcrt1/OxA reaction product in some parts of its cytoplasm (Hcrt1/OxA-Ax1), while the other (Hcrt1/OxA-Ax2) is completely
filled by DAB-nickel-immunoprecipitate. (C) Longitudinally-sectioned Hcrt1/OxA unmyelinated axon. (D) Hcrt1/OxA-immunolabelled axon terminal
(Hcrt1/OxA-T) that makes an asymmetric synapse (curved arrow) on an unlabelled dendrite (Den). Note the presence of Hcrt1/OxA-immunoreaction
product in dense-cored vesicles (dcv), large dcv (ldcv) and in specific regions of the cytoplasm. (E) Hcrt1/OxA-immunoreactivity is observed exclusively
within large dense-cored vesicles (ldcv) of an axon terminal (Hcrt1/OxA-T). (F) Varicosity showing a dense DAB-nickel precipitate for Hcrt1/OxA in ldcv
and the cytoplasm. Scale bar, A-C, E-F,0.2 μm; D, 0.5 μm.
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animals (F5,16 = 1.65; p = 0.20).
A small percentage of Hcrt1/OxA-containing axons
established cellular contacts (appositions and synapses) with
cellular bodies or dendrites of VTA neurons (11.20% ±
1.31%; Figure 6; Table 2). Hcrt1/OxA-immunoreactive
axonal boutons preferentially made appositional contacts
with VTA dendrites (n = 80; Table 2), most of which were
unlabeled. In those cases in which synaptic specializations
were evident, they were asymmetric (excitatory type;
n = 22; Figure 7), and mainly formed with unlabeled
dendrites (68.18%; Figure 7C,D), but contacts werealso established with FG-labeled dendrites (31.82%;
Figure 7A,B). Moreover, we observed one axo-somatic
and one axo-axonic synapse with unlabeled profiles.
The presence of cellular contacts made by Hcrt1/OxA-
immunolabeled boutons was frequently associated with a
given morphological type of axonal bouton (χ21 = 7.18;
p = 0.007). Hcrt1/OxA-immunoreactive axon terminals
established about twice as many cellular contacts
(apposition and synapse) as Hcrt1/OxA-immunolabeled
varicosities. Furthermore, analysis of the synaptic propor-
tions with respect to all cellular contacts made by both
types of bouton (varicosity or axon terminal), showed that
Figure 6 Bar graph showing the percentage distribution of
contact types (apposition [App] or asymmetric synapse [Syn])
or absence of contact (No cont) between Hcrt1/OxA-containing
unmyelinated axons (Ax) or boutons (B) with ventral tegmental
area dendrites that are unlabeled (un) or Fluorogold-labeled
(FG). Percentages (mean ± SE) were obtained from 14 vibratome
sections of 6 rats, representing the distribution of a total number of
2,174 Hcrt1/OxA-immunolabeled axons with respect to their
contacts with dendrites within the ventral tegmental area.
Del Cid-Pellitero and Garzón BMC Neuroscience 2014, 15:105 Page 8 of 17
http://www.biomedcentral.com/1471-2202/15/105Hcrt1/OxA-labeled axon terminals made more synapses
than varicosities (58.33% versus 16.67% of total contacts).
Thus, Hcrt1/OxA axon terminals preferentially formed
asymmetric synapses while Hcrt1/OxA varicosities mainly
established appositional contacts (Figure 7E; Table 2). This
association between axonal bouton type (varicosity or
terminal) and cellular contact type (apposition or synapse)
was assessed using the chi-square test for the raw number
of contacts made by Hcrt1/OxA-immunoreactive boutons
(χ21 = 10.87; p = 0.001; Table 2). Most of the dendrites that
established asymmetric synapses with Hcrt1/OxA-labeled
boutons had a mean diameter greater than 0.8 μm
(62.50%; Figure 7F), suggesting they were close to the
neuronal somata. We only observed one Hcrt1/OxA
varicosity that formed a synapse with an unlabeled
dendrite that had a diameter less than 0.5 μm. Some
dendrites that established synapses with Hcrt1/OxA
boutons also received inputs from unlabeled axon terminalsTable 2 Appositional contacts and synapses established








FG Unlabeled FG Unlabeled
Unmyelinated axon (n = 1558) 42 96 2 5 145
Varicosity (n = 579) 20 55 4 11 90
Axon terminal (n = 37) 5 0 3 4 12
Total 67 151 9 20 247
Raw numbers of appositional contacts and synapses made by Hcrt1/OxA
axonal profiles in the ventral tegmental area with either Fluorogold (FG)-labeled
or unlabeled dendrites. Data were collected from 14 vibratome sections
processed for dual labeling (Hcrt1/OxA and FG) in 6 rats that had been injected
with FG in the prelimbic sector of the medial prefrontal cortex.that made cellular contacts (appositions or synapses) with
FG-labeled dendrites.
A few Hcrt1/OxA-containing unmyelinated axons, most
of them transversely-sectioned, formed appositional
contacts (138/1559; Figure 7A) with VTA dendrites
[unlabeled (3.59% ± 0.88%); FG-labeled (2.19% ± 0.46%)].
In only two rats (R31 and R35) did these axons make
some asymmetric synapses onto dendrites [unlabeled
(5/1558); FG-labeled (2/1558); Table 2]. Furthermore,
Hcrt1/OxA-containing axons were close to blood vessels
or even in contact with the vascular glia limitans
(Figure 8). In our sample, around 2% of the Hcrt1/OxA-
immunoreactive axons were located at a distance of
less than 0.6 μm from the vascular basal membrane
(1.99% ± 0.42%); approximately half of these axons close
to blood vessels were boutons (1.07% ± 0.60%).
Discussion
The Hcrt/Ox system sustains arousal [26] and supports
the transition of sleep-wakefulness cycle states [27]. In the
present study, we suggest that some of these Hcrt/Ox
functions could be mediated by their actions on VTA
neurons (dopaminergic and non-dopaminergic) that
project to the mPFC. Furthermore, we demonstrate that
non-dopaminergic neurons constitute a major source of
the mesocortical pathway to mPFC.
Methodological considerations
The tracer FG was used because it can be retrogradely
transported to neuronal somata that are a long distance
from the tracer deposit, and it can be detected by different
immunohistochemical techniques that amplify the FG
signal [28,29]. However, we cannot exclude the possibility
that some axon terminals did not take up the FG and the
retrogradely-labeled neurons would be underestimated.
Injection parameters such as current intensity, duration of
injection and micropipette tip diameter were the optimal
to obtain small injections that would include all cortical
layers without producing cortical lesions. All antisera used
have a high specificity and have been used in previous
studies [28,30,31]. Moreover, omission of the primary
antibodies resulted in the absence of immunoreactivity.
The Hcrt1/OxA antiserum has been characterized at
light and electron microscope levels and it does not
cross-react with Hcrt2/OxB antisera [30]. What is more,
Hcrt1/OxA-immunolabeling was never observed in
somatodendritic profiles, but only in axons in the VTA, as
we would have expected, whereas FG is mainly associated
with lysosomes and multivesicular bodies of proximal
dendrites and somata. FG-immunoprecipitate was also
observed in confined zones of the cytoplasm. Hcrt1/OxA
detection was amplified using immunoperoxidase-nickel-
intensification, and the intense electrodense labeling was
easily discernible from FG-immunoprecipitate. Overall, the
Figure 7 Cellular contacts established by Hcrt1/OxA-containing axons in the ventral tegmental area. (A) Hcrt1/OxA-immunoreactivity is
seen in large dense-cored vesicles (ldcv), dense-cored vesicles (dcv) and in the cytoplasm of a varicosity (Hcrt1/OxA-V) that makes an asymmetric
synapse (curved arrow) with a Fluorogold-labeled dendrite (FG-den). The FG-den is identified by its content in DAB-immunoperoxidase reaction
product (black arrows). (B) Hcrt1/OxA-V establishes an asymmetric synapse (curved arrow) with a FG-dendrite that receives convergent input from
an unlabeled axon terminal (Ter). (C) A VTA dendrite (Den) receives a synaptic contact (curved arrow) from an Hcrt1/OxA-immunoreactive varicosity
(Hcrt1/OxA-V) and an unlabeled Ter. (D) Hcrt1/OxA-T makes an asymmetric synapse (curved arrow) on an unlabeled Den. Hcrt1/OxA-T contains
translucent small synaptic vesicles (ssv) near the synaptic specialization while dcv are far from the synapse. (E) Bar graph showing the relative percentage
of appositional and synaptic contacts (asymmetric) established by Hcrt1/OxA-boutons with unlabeled- (un) or FG-labeled (FG) dendrites according to the
type of axonal bouton (varicosity, diameter < 0.7 μm or axon terminal, diameter≥ 0.7 μm) in the ventral tegmental area. Mean percentages and standard
errors were calculated based on the numbers obtained from 102 Hcrt1/OxA-immunoreactive boutons in 14 vibratome sections from six rat brains. (F) Bar
graph showing the percentage distribution of unlabeled and Fluorogold-labeled (FG) dendrites of different sizes receiving asymmetric synapses (n = 22)
from Hcrt1/OxA-immunolabeled axonal boutons (terminals and varicosities; total sample: 616 boutons) in the ventral tegmental area. Mean percentages
and standard errors were calculated based on the numbers obtained from the synapse-recipient 22 dendrites in 18 ultrathin sections from 6 rat brains.
ANOVA (animal X dendritic size) was done to determine in those dendrites significant variations in the formation of asymmetric synapses with respect to
their small (<0.5 mm), intermediate (0.5-1.0 mm) or large (>1.0 mm) diameters [*p < 0.05; post hoc Fisher test]. Scale bar, 0.2 μm.
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identification of specific labeling in material in which
there was almost no background, as judged by strayimmunoprecipitate over resin, myelin, or other structures
not expected to express the antigens they were raised
against.
Figure 8 Hcrt1/OxA-containing axons close to blood vessels (bv) in the ventral tegmental area. (A) An Hcrt1/OxA-immunoreactive axonal
bouton (Hcrt1/OxA-B) forms an appositional contact with a muscle cell (mc) in an arteriole. (B) Hypocretinergic/orexinergic varicosity (Hcrt1/OxA-V),
containing large dense-cored vesicles (ldcv), is near a bv. (C) Unmyelinated axon containing Hcrt1/OxA (Hcrt1/OxA-Ax) close to a bv, makes an
appositional contact (arrowhead) with a Fluorogold-labeled dendrite (FG-den, black arrow). e, endothelial cell. Scale bar, A, 0.5 μm; B-C, 0.2 μm.
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only made a few synaptic contacts, we should recall that
synaptic specializations occupy a small proportion of the
neuron membrane surface and we did not study serial
ultrathin sections. Thus, we cannot exclude the possibility
that Hcrt1/OxA-immunolabeled axons might have formed
synaptic contacts with FG-labeled neurons in sectional
planes other than the ones observed here. Moreover, pre-
embedding methods can underestimate the associations
between immunoreactive profiles [32]. In addition, since
we injected only a small cortical area (PL), but VTA has a
widely distributed projection system to cerebral cortex [4],
the observed synaptic contacts with FG-dendrites are only
a fraction of the total synapses onto mesocortical neurons.
However, they represent most of the synaptic contacts with
VTA neurons that project to mPFC, since our injections in
all cases comprised the whole mPFC. Moreover, FG has
proved to have a good efficiency as a tracer for VTA
projections to mPFC in numerous studies [6,28]. The
high sensitivity of FG as retrograde tracer [29,33] suggests
that most mesocortical neurons reaching the mPFC were
detected in our animals. There is no reason to suppose
that Hcrt1/OxA axons innervate preferentially a neuronal
population that had not transported the FG, resulting in
an underestimation of contacts.
Mesocortical system: the relative contribution of
dopaminergic neurons
It is known that many cognitive and attentional processes
characteristic of wakefulness are mediated by VTA projec-
tions to mPFC [34]. Our FG-labeled neurons were mainly
located in the ipsilateral parabrachial division of the VTA
as reported in similar studies previously done in rats
[5,35,36] and monkeys [37], even though in some of those
studies the injections were more posterior and included allthe anterior cingular cortex [5]. More recent studies
have described that PL injections mainly label neu-
rons within the parabrachial VTA of the rat [28], but
some others have reported to label equal numbers of
paranigral and parabrachial neurons after injections in
posterior areas of anterior cingular and prelimbic cortices
in mice [38].
Our finding of many non-DA VTA neurons projecting
to the mPFC agrees with previous results in rats from
Swanson (1982) [5], Carr & Sesack [6] and Lammel et al.,
[38]. In addition to DA neurons, glutamate and GABA
neurons are present in the VTA [2,3], but the distribution
of these neuronal populations in the different subdivisions
of the VTA is heterogeneous. Although PBP contains
many DA neurons [2], the VTA PBP neurons projecting
to PFC observed in this study and another [5] are mainly
non-dopaminergic. Moreover, subcellular studies have
determined that around 60% of VTA neurons projecting
to mPFC contain GABA [6]. Furthermore, Lammel et al.,
[38] have also described that DA neurons projecting to
PFC were located mainly in the PN and caudal PBP
subdivisions of VTA, while neurons in the rostral
PBP subdivision that project to mPFC were mostly
non-DA, as occurred in our animals.
VTA actions on the frontal cortex are mediated by
both DA and non-DA neurons. Since non-DA mediated
cortical activity can be blocked with GABA antagonists,
these mesocortical neurons are presumed to be mainly
GABAergic [8]. Moreover, electrophysiological unit record-
ings combined with immunohistochemical detection have
demonstrated that many VTA mesocortical neurons
supposedly involved in reward behaviors and cortical
arousal [39] are indeed GABAergic [40]. However, we
cannot discard that non-DA mesoprefrontal neurons could
contain some other neurotransmitters such as glutamate,
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[3]. There is also evidence that DA VTA neurons are
unique in their firing rate stability across sleep states [41].
On the contrary, VTA GABA neurons increase firing rates
during active wakefulness and REM sleep in comparison to
quiet wakefulness and non-REM sleep [7]. This suggests
that GABA VTA neurons could be more involved in
extrathalamic cortical activation [7] while DA neurons
seem to be implicated in responses to non-predicted
rewards or salience [42].
Hcrt1/OxA targeting of VTA mesocortical neurons
Previous studies on preproHcrt/preproOx [12] and
Hcrt1/OxA [23] distributions have reported that Hcrt/Ox-
containing axon density in VTA is weaker than in other
nuclei such as the locus coeruleus or dorsal raphe nucleus,
similarly to our results. Balcita-Pedicino & Sesack
[23] observed that Hcrt1/OxA and Hcrt2/OxB had
similar distributions and locations in VTA varicose axons.
These authors described Hcrt/Ox-immunoreactivity as
being located in the cytoplasm and dense-cored vesicles of
different sizes (dense-cored vesicles, dcv and large
dense-cored vesicles, ldcv) within axons. Furthermore,
they reported that only 15% of the Hcrt1/OxA-containing
axons made some cellular contact (apposition or synapse)
with VTA neurons. In our study, the proportion of
Hcrt1/OxA axons that established contacts is somewhat
similar (11.20%) but, in contrast to their description
of both asymmetric and symmetric synapses, we only
observed Hcrt1/OxA axons making asymmetric synapses
on VTA dendrites.
Hcrt1/OxA has been identified in dcv and ldcv pre-
viously [10,43,44]. These kinds of vesicles release their
content by exocytosis [45,46]. Torrealba et al., [43]
have reported Hcrt1/OxA in ldcv and dcv within
axons of the hypothalamic tuberomammillary nucleus.
They observed in the same axon terminals that these
vesicles were localized far from the synaptic specialization,
while translucent small synaptic vesicles near synapses
contained glutamate.
Hcrt1/OxA and Hcrt2/OxB activate both DA and
non-DA VTA neurons [22]. In contrast to Hcrt1/OxA,
Hcrt2/OxB has been reported to increase presynaptic
glutamate release in addition to potentiation of postsyn-
aptic NMDA receptors [47]. Furthermore, Hcrt/Ox
enable glutamate-mediated responses in VTA that are
necessary for glutamate-dependent long-term potentiation
in VTA DA neurons [48]. Thus, Hcrt1/OxA and Hcrt2/
OxB could modulate different behavioral components of
VTA function.
FG injections in PFC combined with ventricular infusion
of Hcrt1/OxA has shown that the neurons projecting to
the PFC that are activated by Hcrt1/OxA are mainly
located in caudal and medial portions of VTA, andthat approximately 50% of them are dopaminergic [19]. In
addition, local infusion of Hcrt1/OxA in VTA increases
wakefulness and DA release in PFC [21].
The common observation of Hcrt1/OxA axons close
to blood vessels, similar to what has been reported in
other brain areas [49-51], suggests an association between
the Hcrt/Ox system and vasomotor control. In fact,
Hcrt/Ox-R1 activation attenuates neurogenic vasodilation
of dural vessels [52]. Hcrt/Ox have also shown vasomotor
effects through its activation of nitrergic or GABAergic
neurotransmission in the solitary tract [53]. Neuropeptide
Y, a well-known peptide involved in microvascular
functions [54], is contained in hypothalamic neurons
targeted by Hcrt/Ox axons [55]. Altogether, this suggests
that the Hcrt/Ox system could be involved in vascular
tone regulation also in the VTA.
Functional considerations
Hcrt/Ox neurons have their highest firing rate in
wakefulness, decrease activity during non-REM sleep,
and are relatively silent in REM sleep [17]. Thus,
Hcrt/Ox help in maintaining wakefulness [26] and mediate
sleep-wakefulness transitions [27]. Hcrt1/OxA actions on
the cortex are partly direct and partly due to activation of
ascending systems reaching the cerebral cortex [56].
However, it is unknown, so far, which of these pathways is
more relevant for arousal and wakefulness. Our results
complement previous studies on Hcrt1/OxA innervation
of brainstem wakefulness-related areas, [49-51], and allow
us to establish cellular and subcellular bases by which the
Hypocretinergic/orexinergic system excites VTA neurons
that project to PL, activating the cerebral cortex. The VTA
is not the only gateway for Hcrt1/OxA neurons to gain
acces to the mPFC. Significant Hcrt1/OxA targeting has
also been described in some other brainstem nuclei
projecting to mPFC, such as the locus coeruleus [49],
dorsal raphe nucleus [50] and laterodorsal tegmental
nucleus [51]. Conceivably, all these structures contribute
to cortical-activating actions of Hcrt1/OxA. The particular
impact of the VTA within those actions seems to be
especially prominent provided the strong dopaminergic
regulation of both sleep attacks and cataplexy in murine
and canine models of narcolepsy [57,58]. The existence of
Hcrt1/OxA-immunoreactive large dense-cored vesicles,
which are quite distant from synaptic specializations in
axons making asymmetric synapses, suggests that
Hcrt1/OxA-containing axons may excite VTA neurons
through both excitatory synapses and non-synaptic
mechanisms, most likely through extracellular diffusion of
the peptide, and activation of receptors away from the
release site [24,25]. Overall, this interpretation might help
explain the hypersomnia of narcoleptic patients as the
result in part of a reduced tone of Hcrt1/OxA arousing
actions in the VTA [59].
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dopaminergic, GABAergic [6,23] or glutamatergic [43].
The localization of Hcrt1/OxA-immunoprecipitate in
axons forming asymmetric synapses and in granular ves-
icles (dcv and ldcv) that are distant from synaptic spe-
cializations, suggests that Hcrt1/OxA most likely
colocalizes with an excitatory neurotransmitter such as
glutamate in the VTA (Figure 9), similar to what has
been described in the tuberomammillary nucleus [43].
Thus, Hcrt1/OxA could enhance the actions of an
excitatory neurotransmitter during longer periods of
time by rising excitability of common postsynaptic
target neurons and/or temporal/spatial summation of
individual actions of Hcrt1/OxA and the excitatory
transmitter. Moreover, Hcrt/Ox inhibit brain structuresFigure 9 Schematic drawing depicting the possible cellular mechanis
tegmental area (VTA). Hcrt1/OxA-containing axons (Hcrt1/OxA-Ax) make
of which (Fluorogold-labeled dendrite, FG-den) belong to neurons that pro
small synaptic vesicles (ssv) release their content to the synaptic cleft, activatin
dcv and large dcv, ldcv) may release Hcrt1/OxA far from synaptic specialization
a distance and more slowly. Both mechanisms (synaptic and non-synaptic) are p
to cortical activation and wakefulness maintenance. bv, blood vessel; Hcr
axon terminal; Hcrt1/OxA-V, Hcrt1/OxA-containing varicosity.involved in non-REM sleep generation, such as the
preoptic area [20,60,61] and also blocks structures
involved in REM sleep such as the ventral part of oral
pontine tegmentum [62,63].
Conclusion
In the present study we demonstrate that Hcrt/Ox
hypothalamic neurons may activate the medial pre-
frontal cortex through VTA neurons (dopaminergic
and non-dopaminergic), contributing to the arousal and
wake-enhancing functions typical of this cortical area.
Hcrt1/OxA-containing axons may excite VTA neurons
through both excitatory synapses and non-synaptic
mechanisms (volume transmission). Both mechanisms
(synaptic and volumetric) probably play important roles inms whereby Hcrt1/OxA activates neurons in the ventral
asymmetric synapses (excitatory type) with VTA dendrites (Den), some
ject to the medial prefrontal cortex. In the Hcrt1/OxA axons, translucent
g postsynaptic receptors, while granular vesicles (dense-cored vesicles,
s and activate extrasynaptic receptors (Hcrt/Ox-R) by volume transmission at
resumably involved in Hcrt/Ox actions in the VTA, thus contributing
t/Ox-R, receptor binding Hcrt1/OxA; Hcrt1/OxA-T, Hcrt1/OxA-containing
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wakefulness-sleep states and maintaining arousal.
Methods
Fluorogold injections
Eighteen male adult Sprague–Dawley rats weighing
250-300 g were used in this study. All animal procedures
were done in strict accordance to European Community
Council Directive (86/609/EEC), and the used protocol
was approved by the Ethical Committee for the use
of laboratory animals of the Universidad Autónoma
de Madrid. All efforts were made to minimize animal
suffering.
To label VTA neurons projecting to mPFC, the
retrograde tracer Fluorogold (FG; Fluorochrome,
Englewood, CO) was microinjected into the prelimbic
mPFC, extending in some cases to medial orbital and/or
cingular sectors, using previously described methods [28].
The animals were anaesthetized with a cocktail of
Ketamine (55 mg/kg i.m.), Xylacine (15 mg/kg i.m) and
Atropine (0.2 mg/kg i.m.). Glass micropipettes were pulled
to obtain 10-15 μm diameter tips and were filled with a
1.5% solution of FG in isotonic saline. The micropipettes
were stereotaxically placed unilaterally in the mPFC
(2.7 mm anterior to bregma; 0.4 mm lateral from midline;
3.7 mm ventral from skull dorsal surface), as determined
from the rat brain atlas of Paxinos & Watson (1998) [64].
FG was injected iontophoretically using continuous
current (positive 5 μA, on 8sg/ off 8sg) for 10–15 minutes.
The micropipettes were left in place from 5 minutes
before to 5 minutes after the injection to avoid spread
of the solution. The skin incision was closed with a
surgical thread and topical lidocaine was applied. The
rats were returned to the animal colony and housed in
individual cages. They were allowed unlimited access to
water and food and were maintained in a 12 h light/12 h
dark cycle for six days.
Tissue preparation
Rats were perfused six days after FG injections, a time
that has been shown optimal for retrograde tracing of
VTA neurons after prefrontal cortex injections [33]. The
rats were anaesthetized with sodium pentobarbital
(33 mg/Kg i.p.) and their brains were fixed by aortic arch
perfusion with heparin in saline (1000 U/ml) and 0.2%
glutaraldehyde in a solution of 4% paraformaldehyde
in 0.1 M phosphate buffer, pH 7.4 (PB). The brains were
removed from the skull and coronal blocks containing the
mPFC and the VTA region were obtained. They were
postfixed for 2 hours in 4% paraformaldehyde in 0.1 M PB
at 4°C, and coronal sections of 40-50 μm thickness were
serially collected from these blocks in 0.1 M PB at 4°C,
using a Vibratome Series 3000 (Technical Products
International. Ted Pella. Inc).One of the tissue series was stained using the Nissl
method to locate the injections and the borders of the
brain nuclei and tracts [64,65]. The tissue sections used
for immunohistochemistry were incubated for 15 minutes
in 1% sodium borohydride in 0.1 M PB to inactivate free
aldehydes and 15 minutes in 10% methanol and 10%
hydrogen peroxide in 0.1 M PB to inactivate endogenous
peroxidase. Then, the sections were processed for immu-
nohistochemical labeling as described below. After the
immunolabeling procedures, sections for light microscopy
observation were rinsed in 0.03 M PB and mounted
on gelatine-coated glass slides, dried, dehydrated in a
series of ascending concentrations of ethanol, defatted
in xylene and coverslipped with DPX mounting medium
(Sigma-Aldrich, St. Louis, CA).
Single immunohistochemical detection of Fluorogold
Sections containing either mPFC (15 sections per animal)
or the VTA (8 sections per animal) region were processed
immunohistochemically for light microscope observation of
the injection site and retrograde tracing, respectively. They
were first rinsed in 0.1 M PB and incubated 30 minutes in
0.5% bovine serum albumin (BSA; Sigma-Aldrich, St. Louis,
CA) in 0.1 M PB to minimize non-specific background
staining. They were then incubated overnight in rabbit
anti-FG antibody (1:4000; AB153; Chemicon, Temecula,
CA), 0.1% BSA and 0.25% Triton X-100 in 0.1 M PB
protected from light at room temperature. After this, the
sections were incubated in biotinylated goat anti-rabbit
IgG (1:400; AP132B; Chemicon, Temecula, CA) and in
0.1% BSA in 0.1 M PB for 30 minutes, rinsed in 0.1 M PB
and incubated 1 hour in avidin-biotin peroxidase
complex (1:100; ABC; Vector Lab, Burlingame, CA).
Peroxidase was visualized as a brown precipitate by
incubation of the tissue in 0.022% 3,3´-diaminobenzidine
(DAB) and 0.0033% hydrogen peroxide in 0.1 M PB at 4°C
for 6–10 minutes.
Dual immunofluorescence detection of Fluorogold and
tyrosine hydroxylase
One of the tissue series was processed for immunofluores-
cent detection of the retrograde tracer FG and of tyrosine-
hydroxylase (TH, marker for dopamine-containing neurons
in the VTA). All procedures were done protecting the tissue
from light. After extensive rinsing in 0.1 M phosphate-
buffered saline pH 7.4 (PBS), the sections were incubated in
citrate buffer pH 6.0 at 90°C for 10 minutes. Then the
sections were incubated in 10% donkey serum, 1%
BSA and 1% Triton X-100 in 0.1 M PBS for 2 hours at
room temperature. Afterwards, tissue sections were
incubated in 1) rabbit anti-FG (1:1500; AB153; Chemicon,
Temecula, CA) and 2) mouse anti-TH (1:1000; 22941;
ImmunoStar Inc, Hudson, WI) in 3% donkey serum,
0.3% BSA and 0.3% Triton X-100 in 0.1 M PBS at 4°C for
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incubated in donkey anti-rabbit IgG 488 nm (1:100;
A21206; Alexa Fluor, Invitrogen, Carlsbad, CA) and
donkey anti-mouse IgG 570 nm (1:100; 715-025-150;
Jackson ImmunoResearch, West Grove, PA) in 0.1 M
PBS at 4°C for 2 hours.
Single immunohistochemical detection of
Hypocretin1/OrexinA
Four additional naive male Sprague–Dawley adult rats
weighing 250-300 g were used in these experiments. The
Hcrt1/OxA antiserum used was raised in goat against a
19 residue-peptide fragment located at the C-terminus of
human Hcrt1/OxA (aa 48–66 of the Hcrt/Ox precursor
identical to the corresponding rat/mouse sequence). This
antiserum has a highly specific distribution in multiple
brain regions [17,66]. Specificity of the anti-Hcrt1/OxA
antiserum has been previously tested by Western blot and
immunohistochemistry tests; the antiserum detects the
processed active Hcrt1/OxA peptide of rat origin but it
does not recognize or cross-react with Hcrt2/OxB [30].
Moreover, the specificity of the Hcrt1/OxA-labeling in the
present study is also supported by the results of negative
control experiments, and the species selectivity testing of
the secondary antiserum.
Tissue sections were incubated in 10% donkey
serum (Sigma-Aldrich, St. Louis, MO) in 0.1 M PB
for 3 hours. They were then placed sequentially in: 1) goat
anti-Hcrt1/OxA antiserum (1:2000; C-19: sc-8070; Santa
Cruz Biotechnology Inc, St. Cruz, CA), 2% donkey serum
and 0.25% Triton X-100 in 0.1 M PB at 4°C for 48 hours; 2)
biotinylated donkey anti-goat IgG (1:400; AP180B;
Chemicon, Temecula, CA) and 2% donkey serum in
0.1 M PB for one hour; and 3) ABC (1:100) in 0.1 M PB
for an hour. Hcrt1/OxA was visualized as an intense
black precipitate using a modification of the glucose
oxidase-DAB-nickel method [67].
Dual immunohistochemical detection of Hypocretin1/OrexinA
and Fluorogold
Tissue sections of the VTA from the eighteen FG-injected
rats were processed for dual detection of Hcrt1/OxA
and FG. Non-specific tissue epitopes were blocked by
incubation in 10% donkey serum in 0.1 M PB for 3 hours
before incubating the sections in goat anti-Hcrt1/OxA
(1:2000), 0.03% Triton X-100 and 2% donkey serum in
0.1 M PB at 4°C for 48 hours. Afterwards, the sections
were incubated in biotinylated donkey anti-goat IgG
(1:500) in 0.1 M PB for 2 hours, and in ABC (1:100) in
0.1 M PB for 1 hour. Hcrt1/OxA detection was completed
by using the glucose oxidase-DAB-nickel method as
described earlier. After abundant rinsing in 0.1 M
acetate buffer pH 6.0 and in 0.1 M PB, the sections
were sequentially incubated in 1) rabbit anti-FG antiserum(1:4000) and 2% donkey serum in 0.1 M PB at room
temperature overnight; 2) unconjugated donkey anti-rabbit
IgG (1:50; AP182; Chemicon, Temecula, CA) 2% donkey
serum in 0.1 M PB for 30 minutes; and then, 3) rabbit
peroxidase anti-peroxidase (1:500; PAP18; Chemicon,
Temecula, CA) in 0.1 M PB for 2 hours. The peroxidase re-
action product was visualized by incubation of the tissue in
0.022% DAB and 0.0033% hydrogen peroxide in 0.1 M PB
for 10 minutes. The light brown immunoperoxidase
reaction product identifying FG-labeled neurons was
easily distinguishable from the nickel-intensified black
reaction product that marked Hcrt1/OxA fibers.
Electron microscopy
Six animals, which had FG injections restricted to the
prelimbic cortex, were used for the ultrastructural study
of dual Hcrt1/OxA and FG localization. Immunolabeled
sections were postfixed in 2% osmium tetroxide in
0.1 M PB for an hour, dehydrated through a series of
increasing ethanol concentrations and propylene oxide,
and incubated overnight in a 1:1 mixture of propylene
oxide and epoxy resin (Epon; EMbed-812; Electron
Microscopy Sciences, Fort Washington, PA). The sections
were transferred to 100% Epon for 2 hours, flat-embedded
in Epon between two sheets of plastic film and cured at
60°C for 72 hours. Fragments of the VTA ipsilateral to the
injection area at the approximate level of anteroposterior
plane −5.3 mm from bregma were cut from the
Epon-embedded sections and glued onto resin blocks.
Ultrathin sections (40-50 nm) were obtained from the
tissue-Epon interface using a diamond knife (Diatome MT
8618) within an ultramicrotome (Reichter-Jung, Ultracut
E/GA/S-83/05; Vienna, Austria) and were collected on
300-mesh copper grids. Then, the ultrathin sections
were counterstained with 5% uranyl acetate in water
for 20 minutes followed by a solution containing
0.022 mg lead citrate in 0.5 ml NaOH and 4.5 ml distilled
water for 4–6 minutes. They were examined with a Jeol
JEM 1010 electron microscope (Tokyo, Japan) coupled to
a Bioscan camera (Gatan Inc.).
Data analysis
The tissue sections processed for single and dual-
immunohistochemistry were studied with a Nikon Eclipse
E600 microscope. Selected representative photographs of
labeling for FG and/or Hcrt1/OxA were taken with the
microscope equipped with a digital camera (digital camera
DXM1200, Nikon) and appropriate computer software
(Nikon Camera Software DXM1200 ACT-1). Adjacent Nissl
sections were used to delimit FG deposits in mPFC
(Figure. 1A) and to draw the retrograde-labeled neurons
within the VTA (Bregma −5.3 mm to −6.8 mm). Outlines
of sections and major brain structures were drawn by
overlapping FG-immunolabeled sections and the adjacent
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leitz GMBH Wetzler; objective Milaron 1:2:5/90 mm);
these drawings were scanned (EPSON Expression 1600)
and FG-labeled neurons were plotted by using light micro-
scope high magnification (20-40x). Two-way analyses of
variance (ANOVA; labeling side X injection site group)
were used to determine whether there was significant
variability in the proportions of FG-immunolabeled
neurons with respect to (1) ipsilateral versus contralateral
side to the FG injection, and (2) location of injection site
in mPFC (PL, Cg1-PL or PL-MO).
Immunofluorescence sections were examined by
biomapping using a confocal microscope (Leica TCS SP2
Spectral microscope; Leica Microsystems, Germany); VTA
area was studied in 1 μm thick optical sections obtained
through the depth of the tissue with a 20X multi-immersion
objective. FG single-labeled cells and FG/TH dual-labeled
cells were counted throughout the VTA (n = 18). Analysis
of variance (ANOVA) followed by Fisher’s least significant
difference (PLSD) test were used to determine whether
there were statistically significant variations in the
percentage of these two neuronal populations between
(1) immunolabeling side (ipsilateral versus contralateral to
FG injection), and (2) different injection site groups (PL,
Cg1-PL and PL-MO). Nested ANOVAs (labeling side X
injection site X staining method) were used to assess the
statistically significant variations in the proportions of
single (FG) and dual (FG/TH) neurons in the three
injection site groups (PL, Cg1-PL and PL-MO) using
either immunohistochemistry or immunofluorescence. We
also applied Chi-square test to determine the association
among staining method and injection site group. The
immunolabeled images and drawings were assembled and
labeled with text in Canvas (Canvas X, ACD Systems
International Inc., Canada) to obtain the composite
figures depicting FG localization. Moreover, we determined
the exact location of FG-labeled neurons in the different
subdivisions of the VTA based on Halliday& Törk (1986) [1].
The ultrastructural analysis was carried out in 14
vibratome sections that were obtained from six rats
(at least two sections per animal). Two ultrathin sections
respectively cut from opposite sides of the vibratome
sections (≥10 μm apart) were obtained in each animal from
resin blocks including a VTA section. All immunoreactive
processes (n = 2186) were counted in randomly sampled
electron micrographs at 50,000x magnification from an area
of 1,946,455.5 μm2 within an area of at least 90,859.96 μm2
examined in each animal. The classification of identified
cellular elements was based on standard descriptions [68].
Axons were recognized by their small caliber and their lack
of ribosomes. The maximum diameter along the short
axonal axis was measured in Hcrt1/OxA-immunoreactive
profiles as a criterion for estimating the real diameter of the
profile regardless of the plane of section. The diameter isdirectly proportional to the cross-sectional surface of a
profile, especially in rather cylindrical structures such as
axons. We measured the circularity [4π(area/perimeter2)]
in all the Hcrt1/OxA-containing axons. This parameter is a
mathematical factor that indicates how close the diameter
of a profile is to a perfect circle. Thus, circularities over 0.7
would indicate an axon was sectioned quite close to its
transverse plane, while progressively lower circularities are
found in axons that are longitudinally- or non-transversely-
sectioned. Chi-square test (axonal profile type X circularity)
was calculated to validate our method for measuring profile
diameter regardless plane of section.
When sectioned transversely, axons had smooth
contours and were often grouped in bundles. Longitudinally
cut axons usually displayed varicosities with vesicles. Axon
boutons were identified by the presence of numerous syn-
aptic vesicles and were ≥ 0.236 μm in diameter. Varicosities
(boutons en passant) ranged 0.236-0.699 μm in diameter
and axon terminals were >0.7 μm, as measured both in
random 100× micrographs in the light microscope images
(ImageJ 1.40 software, National Institutes of Health, USA),
and also in obviously longitudinally-sectioned varicose
axons in electron microscope images. Thus, these criteria
were used to classify an axonal profile as a varicosity or a
terminal. Intervaricose segments of unmyelinated axons
were < 0.236 μm wide and might or might not contain some
vesicles. Dendrites usually contained abundant endoplasmic
reticulum and were distinguished from unmyelinated axons
by their larger diameter and/or prevalence of uniformly
distributed microtubules. Neuronal somata were recognized
by the presence of a nucleus, Golgi apparatus and rough
endoplasmic reticulum. Both dendrites and somata were
often found postsynaptically to axonal boutons. Synaptic
contacts were classified as symmetric or asymmetric based
on the characteristics of their pre- and postsynaptic
densities. Zones of closely spaced parallel plasma mem-
branes that lacked discernible synaptic densities, but were
otherwise not separated by glial processes, were defined
as appositions or non-synaptic contacts. All Hcrt1/OxA-
immunoreactive axons within each ultrathin section were
photographed at 50,000x with a digital camera coupled to
the electron microscope and saved in TIFF format. The
tissue was examined to determine: (1) the relative fre-
quency with which Hcrt1/OxA immunoreactivity was
located within axon boutons, unmyelinated axons or
myelinated axons; (2) Hcrt1/OxA-immunolabeling area
density (number of Hcrt1/OxA-immunolabeled profiles
per analyzed surface unit) for each animal and ultrathin
section; (3) the number and type of morphologically-
recognizable synaptic or appositional contacts established
by Hcrt1/OxA processes with FG-labeled or unlabeled
profiles; and (4) measurements of area, perimeter, circular-
ity and mean diameter of each Hcrt1/OxA-labeled profile
(ImageJ). Analysis of variance (ANOVA) tests followed by
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mine whether there was significant variability in
Hcrt1/OxA-immunolabeling area density with respect
to different animals or sections. We also calculated
ANOVAs (animal X axonal profile type X circularity) to
assess significant statistical variations between animals in
the distribution of transversely- and longitudinally-sectioned
axons. Chi-square tests were used to determine the associ-
ation among axonal profile type and the category of contact
established (apposition or synapse). Significant statistical
variations in the proportions of dendrites with different sizes
receiving input from Hcrt1/OxA-immunolabeled boutons
were evaluated with ANOVA (animal X dendritic diameter).
Post hoc multiple pair analysis were made using Fisher's
pairwise comparison test. All statistical analyses were
carried out with the aid of Statview software (V 5.0; SAS
Institute, Cary, NC, USA). Canvas X software was used to
build and label the composite illustrations.
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